With the hype around generative AI (GenAI), there is an increasing demand to explore its capabilities across pharma and MedTech companies, as well as contract research organisations.
The future of cancer care is personalisation. New breakthroughs are increasingly highly targeted, with powerful results, but only for patients with particular genetic markers.
In today’s world, customers are bombarded with advertisements everywhere they turn. Open any social media platform, and there they are. Check your email inbox, and there are more of them.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh